SARS-CoV-2 multi-variant rapid detector based on graphene transistor functionalized with an engineered dimeric ACE2 receptor

Reliable point-of-care (POC) rapid tests are crucial to detect infection and contain the spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The emergence of several variants of concern (VOC) can reduce binding affinity to diagnostic antibodies, limiting the efficacy of the currently adopted tests, while showing unaltered or increased affinity for the host receptor, angiotensin converting enzyme 2 (ACE2). We present a graphene field-effect transistor (gFET) biosensor design, which exploits the Spike-ACE2 interaction, the crucial step for SARS-CoV-2 infection. Extensive computational analyses show that a chimeric ACE2-Fragment crystallizable (ACE2-Fc) construct mimics the native receptor dimeric conformation. ACE2-Fc functionalized gFET allows in vitro detection of the trimeric Spike protein, outperforming functionalization with a diagnostic antibody or with the soluble ACE2 portion, resulting in a sensitivity of 20 pg/mL. Our miniaturized POC biosensor successfully detects B.1.610 (pre-VOC), Alpha, Beta, Gamma, Delta, Omicron (i.e., BA.1, BA.2, BA.4, BA.5, BA.2.75 and BQ.1) variants in isolated viruses and patient's clinical nasopharyngeal swabs. The biosensor reached a Limit Of Detection (LOD) of 65 cps/mL in swab specimens of Omicron BA.5. Our approach paves the way for a new and reusable class of highly sensitive, rapid and variant-robust SARS-CoV-2 detection systems

Nédemax mese (Leucoselect, Lymphaselect, Bromelain) in the treatment of chronic venous disease: a multicenter , obbservational study

BACKGROUND: Chronic venous disease (CVD)is major health concern; however,there remains a need to improve treatment approaches.Nédemax Mese , a nutritional supplementation consisting of Leucoselect 300 mg,Lymphaselect 100 mg and Bromelain 100 mg, is a patented formulation thah may have a role in the treatment of CVD. In this prospective , multicenter study conducted at 54 Italian centers, we investigated the effectiveness of Nédemax Mese in a large sample of CVD patients

Nédemax® Mese (Leucoselect®, Lymphaselect®, Bromelain) in the treatment of chronic venous disease: a multicenter, observational study

BACKGROUND: Chronic venous disease (CVD)is major health concern; however,there remains a need to improve treatment approaches.Nédemax Mese , a nutritional supplementation consisting of Leucoselect 300 mg,Lymphaselect 100 mg and Bromelain 100 mg, is a patented formulation thah may have a role in the treatment of CVD. In this prospective , multicenter study conducted at 54 Italian centers, we investigated the effectiveness of Nédemax Mese in a large sample of CVD patients